Literature DB >> 29363529

Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients.

Ying Zhao1,2, Shaoying Tan1,3, Tommy Chung Yan Chan4, Quangang Xu1, Jie Zhao1, Da Teng1, Heyun Fu1, Shihui Wei1.   

Abstract

BACKGROUND/AIMS: To investigate the clinical features of Chinese patients with seropositive myelin oligodendrocyte glycoprotein antibody (MOG-Ab) optic neuritis (ON) and patients with seropositive aquaporin-4 antibody (AQP4-Ab) ON.
METHODS: In this retrospective observational study, sera from patients with demyelinating ON were tested for MOG-Ab and AQP4-Ab with a cell-based assay. Clinical characteristics were compared between MOG-Ab-related ON (MOG-ON) and AQP4-Ab-related ON (AQP4-ON), including visual performances, serum autoantibodies and features on MRI.
RESULTS: A total of 109 affected eyes from 65 patients with demyelinating ON (20 MOG-ON and 45 AQP4-ON) were included. The onset age of MOG-ON was younger than AQP4-ON (MOG-ON: 20.2±17.4 years old, AQP4-ON: 35.6±15.7 years old, P=0.001). Onset severity was not different between these two groups (P=0.112), but patients with MOG-ON showed better visual outcomes (P=0.004). Half of the MOG-ON had a relapsing disease course. Nineteen per cent of patients with AQP4-ON presented coexisting autoimmune disorders, but there were no coexisting autoimmune disorders among patients with MOG-ON. Optic nerve head swelling was more prevalent in patients with MOG-ON (P<0.01). Retrobulbar segment involvement of the optic nerve were more common in patients with MOG-ON according to our MRI findings (P<0.01). Patients with MOG-ON showed longitudinally extensive lesion in 30% and chiasm and optic tract involvement in 5%.
CONCLUSIONS: MOG-ON is not rare in Chinese demyelinating patients. It underwent a severe vision loss at onset but had relatively better visual recovery than patients with AQP4-ON. MOG-ON might have an unique pathogenesis different from AQP4-ON. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  aquaporin-4 antibody; clinical features; magnetic resonance imaging; myelin oligodendrocyte glycoprotein antibody; optic neuritis; visual performances

Mesh:

Substances:

Year:  2018        PMID: 29363529     DOI: 10.1136/bjophthalmol-2017-311177

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

Review 1.  Current understanding of the epidemiologic and clinical characteristics of optic neuritis.

Authors:  Masanori Nakazawa; Hitoshi Ishikawa; Taiji Sakamoto
Journal:  Jpn J Ophthalmol       Date:  2021-05-22       Impact factor: 2.447

Review 2.  Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.

Authors:  Deena A Tajfirouz; M Tariq Bhatti; John J Chen
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

3.  Differences in Clinical Features of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in White and Asian Race.

Authors:  Tanyatuth Padungkiatsagul; John J Chen; Panitha Jindahra; Tetsuya Akaishi; Toshiyuki Takahashi; Ichiro Nakashima; Takayuki Takeshita; Heather E Moss
Journal:  Am J Ophthalmol       Date:  2020-07-15       Impact factor: 5.258

4.  Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.

Authors:  John J Chen; Eoin P Flanagan; Jiraporn Jitprapaikulsan; Alfonso Sebastian S López-Chiriboga; James P Fryer; Jacqueline A Leavitt; Brian G Weinshenker; Andrew McKeon; Jan-Mendelt Tillema; Vanda A Lennon; W Oliver Tobin; B Mark Keegan; Claudia F Lucchinetti; Orhun H Kantarci; Collin M McClelland; Michael S Lee; Jeffrey L Bennett; Victoria S Pelak; Yanjun Chen; Gregory VanStavern; Ore-Ofe O Adesina; Eric R Eggenberger; Marie D Acierno; Dean M Wingerchuk; Paul W Brazis; Jessica Sagen; Sean J Pittock
Journal:  Am J Ophthalmol       Date:  2018-07-26       Impact factor: 5.258

5.  OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS.

Authors:  John J Chen; Elias S Sotirchos; Amanda D Henderson; Eleni S Vasileiou; Eoin P Flanagan; M Tariq Bhatti; Sepideh Jamali; Eric R Eggenberger; Marie Dinome; Larry P Frohman; Anthony C Arnold; Laura Bonelli; Nicolas Seleme; Alvaro J Mejia-Vergara; Heather E Moss; Tanyatuth Padungkiatsagul; Hadas Stiebel-Kalish; Itay Lotan; Mark A Hellmann; Dave Hodge; Frederike Cosima Oertel; Friedemann Paul; Shiv Saidha; Peter A Calabresi; Sean J Pittock
Journal:  Mult Scler Relat Disord       Date:  2022-01-11       Impact factor: 4.339

Review 6.  Update on glial antibody-mediated optic neuritis.

Authors:  Honglu Song; Huanfen Zhou; Shihui Wei
Journal:  Jpn J Ophthalmol       Date:  2022-07-27       Impact factor: 2.211

7.  Risk of Autoimmune Diseases Following Optic Neuritis: A Nationwide Population-Based Cohort Study.

Authors:  Kevin Sheng-Kai Ma; Chee-Ming Lee; Po-Hung Chen; Yan Yang; Yi Wei Dong; Yu-Hsun Wang; James Cheng-Chung Wei; Wen Jie Zheng
Journal:  Front Med (Lausanne)       Date:  2022-06-13

8.  Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder.

Authors:  Deena Tajfirouz; Tanyatuth Padungkiatsagul; Shannon Beres; Heather E Moss; Sean Pittock; Eoin Flanagan; Amy Kunchok; Shailee Shah; M Tariq Bhatti; John J Chen
Journal:  Mult Scler       Date:  2021-05-12       Impact factor: 6.312

Review 9.  Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment.

Authors:  Sidney M Gospe; John J Chen; M Tariq Bhatti
Journal:  Eye (Lond)       Date:  2020-12-15       Impact factor: 3.775

10.  Clinical characteristics of optic neuritis phenotypes in a 3-year follow-up Chinese cohort.

Authors:  Chaoyi Feng; Qian Chen; Guixian Zhao; Zhenxin Li; Weimin Chen; Yan Sha; Xinghuai Sun; Min Wang; Guohong Tian
Journal:  Sci Rep       Date:  2021-07-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.